NCT00520494View on ClinicalTrials.gov

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Common Variable ImmunodeficiencyAgammaglobulinemia
Interventions
DRUG

Vivaglobin

Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.

Trial Locations (6)

25123

Contact CSL Behring for facility details, Brescia

28007

Contact CSL Behring for facility details, Madrid

T6G 2B7

Contact CSL Behring for facility details, Edmonton

H3H 1P3

Contact CSL Behring for facility details, Montreal

04129

Contact CSL Behring for facility details, Leipzig

00186

Contact CSL Behring for facility details, Roma

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT00520494 - Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency | Biotech Hunter | Biotech Hunter